Skip to content

Visionary ScienceDeveloping first-in-class therapeutics to protect the vision of patients with retinal disease.

Our Focus

ONL Therapeutics is pioneering an entirely new approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway.

Pioneering Revolutionary Sight Preservation

OUR SCIENCE

ONL1204, the company’s lead therapeutic candidate is a first-in-class small peptide Fas inhibitor designed to protect the retina from cell death via both direct and inflammatory signaling in a range of retinal diseases.

OUR MILESTONES

Beginning in 2011, and having raised $14 million to date, we’re methodically working our way towards our steadfast mission: to develop first-in-class therapeutics to protect the vision of patients with retinal disease.

OUR PARTNERSHIPS

As a company, we’re exploring, pushing boundaries, and revolutionizing. But, we couldn’t do any of what we do without the guidance and support of every one of our partners. They make what we do possible.

IN THE NEWS

Recent Highlights